Predicting survival in women with breast cancer and brain metastasis: A nomogram outperforms current survival prediction models

Cancer

Volumn 118, Issue 15, 2012, Pages 3749-3757

  Marko, Nicholas F ^a   Xu, Zhiyuan ^a   Gao, Tianming ^a   Kattan, Michael W ^a   Weil, Robert J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

graded prognostic assessment; outcomes; quantitative epidemiology; recursive partitioning analysis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGE; ARTICLE; BOOTSTRAPPING; BRAIN METASTASIS; BREAST CANCER; CANCER PROGNOSIS; CANCER STAGING; FEMALE; HUMAN; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; METASTASIS; NOMOGRAM; PREDICTIVE VALUE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SURVIVAL PREDICTION; VALIDATION PROCESS;

BRAIN NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; KARNOFSKY PERFORMANCE STATUS; MIDDLE AGED; MODELS, STATISTICAL; NOMOGRAMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TREATMENT OUTCOME;

EID: 84864134608     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26716     Document Type: Article

References (37)

1. Parkin DM, Bray F, Ferlay J, Pisani P,. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55: 74-108.
2. Lin NU, Bellon JR, Winer EP,. CNS metastases in breast cancer. J Clin Oncol. 2004; 22: 3608-3617.
3. Yerushalmi R, Tyldesley S, Kennecke H, et al. Tumor markers in metastatic breast cancer subtypes: frequency of elevation and correlation with outcome. Ann Oncol, 2011.
4. Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010; 28: 3271-3.
5. Tomasello G, Bedard PL, de Azambuja E, et al. Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib. Crit Rev Oncol Hematol 2010; 75: 110-3.
6. Gabos Z, Sinha R, Hanson J, et al. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol. 2006; 24: 5658-3.
7. Mahmoud-Ahmed AS, Suh JH, Lee SY, et al. Results of whole brain radiotherapy in patients with brain metastases from breast cancer: a retrospective study. Int J Radiat Oncol Biol Phys 2002; 54: 810-3.
8. Soerjomataram I, Louwman MW, Ribot JG, et al. An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat 2008; 107: 309-3.
9. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002; 20: 719-3.
10. Burstein HJ, Kuter I, Campos SM, et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2001; 19: 2722-3.
11. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999; 17: 2639-2648.
12. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344: 783-792.
13. Sant M, Aareleid T, Berrino F, et al. EUROCARE-3: survival of cancer patients diagnosed 1990-94-results and commentary. Ann Oncol. 2003; 14 (suppl 5): v61-v118.
14. Botha JL, Bray F, Sankila R, et al. Breast cancer incidence and mortality trends in 16 European countries. Eur J Cancer. 2003; 39: 1718-1729.
15. American Cancer Society. Breast cancer facts & figures, 2009-2010. Atlanta, GA: The American Cancer Society. Available at:.
16. Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997; 37: 745-751.
17. MacLeod CM,. Evaluation of chemotherapeutic agents. New York, NY: Columbia Univ Press; 1949.
18. Sperduto PW, Berkey B, Gaspar LE, et al. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 2008; 70: 510-3.
19. Sperduto CM, Watanabe Y, Mullan J, et al. A validation study of a new prognostic index for patients with brain metastases: the Graded Prognostic Assessment. J Neurosurg 109 Suppl: 87-9, 2008
20. Sperduto PW, Chao ST, Sneed PK, et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys 2010; 77: 655-3.
21. Sperduto P, Xu Z, Sneed P, et al. A graded prognostic assessment (GPA) for women with breast cancer and brain metastases. J Clin Oncol. 2010; 15s: 1028
22. Sperduto PW, Kased N, Roberge D, et al. Effect of Tumor Subtype on Survival and the Graded Prognostic Assessment for Patients With Breast Cancer and Brain Metastases. Int J Radiat Oncol Biol Phys, 2011
23. Harrell FE Jr, Lee KL, Mark DB,: Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361-87.
24. Eastham JA, Scardino PT, Kattan MW,: Predicting an optimal outcome after radical prostatectomy: the trifecta nomogram. J Urol 179: 2207-10; discussion 2210-1, 2008.
25. Kattan MW, Eastham JA, Stapleton AM, et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998; 90: 766-3.
26. Kattan MW, Wheeler TM, Scardino PT,: Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol. 1999; 17: 1499-3.
27. Iasonos A, Schrag D, Raj GV, et al. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008; 26: 1364-70.
28. Hanley JA, McNeil BJ,. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982; 143: 29-36.
29. Efron B, Tibshirani R,: An introduction to the bootstrap. New York, NY: Chapman & Hall; 1993.
30. Sternberg CN,: Are nomograms better than currently available stage groupings for bladder cancer? J Clin Oncol. 2006; 24: 3819-3820.
31. Kattan MW,: Nomograms are superior to staging and risk grouping systems for identifying high-risk patients: preoperative application in prostate cancer. Curr Opin Urol 2003; 13: 111-3.
32. Mariani L, Miceli R, Kattan MW, et al. Validation and adaptation of a nomogram for predicting the survival of patients with extremity soft tissue sarcoma using a three-grade system. Cancer. 2005; 103: 402-408.
33. Wong SL, Kattan MW, McMasters KM, et al. A nomogram that predicts the presence of sentinel node metastasis in melanoma with better discrimination than the American Joint Committee on Cancer staging system. Ann Surg Oncol. 2005; 12: 282-288.
34. Gold JS, Gonen M, Gutierrez A, et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol 2009; 10: 1045-1052.
35. Graesslin O, Abdulkarim BS, Coutant C, et al. Nomogram to predict subsequent brain metastasis in patients with metastatic breast cancer. J Clin Oncol. 2010; 28: 2032-2037.
36. Mazouni C, Bonnier P, Romain S, et al. A nomogram predicting the probability of primary breast cancer survival at 2- and 5-years using pathological and biological tumor parameters. J Surg Oncol 2011; 103: 746-750.
37. Keam B, Im SA, Park S, et al. Nomogram predicting clinical outcomes in breast cancer patients treated with neoadjuvant chemotherapy. J Cancer Res Clin Oncol. 2011; 137: 1301-1308.